1. Treatment of clinical T4 stage superior sulcus non-small cell lung cancer: a propensity-matched analysis of the surveillance, epidemiology, and end results database
- Author
-
Chang Chen, Rongying Zhu, Junmiao Wen, Fuquan Zhang, Min Fan, Jiayan Chen, Donglai Chen, Di Liu, Yongbing Chen, Shanzhou Duan, and Xinyan Xu
- Subjects
Male ,Lung Neoplasms ,Kaplan-Meier Estimate ,computer.software_genre ,Biochemistry ,surgery ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Surveillance, Epidemiology, and End Results ,Medicine ,Stage (cooking) ,Research Articles ,Aged, 80 and over ,education.field_of_study ,Database ,Hazard ratio ,Middle Aged ,Prognosis ,Survival Rate ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Female ,Research Article ,Adult ,Population ,Biophysics ,Subgroup analysis ,03 medical and health sciences ,stage IV ,Humans ,education ,Lung cancer ,Molecular Biology ,radiotherapy ,Aged ,Proportional Hazards Models ,Retrospective Studies ,SS-NSCLC ,Proportional hazards model ,business.industry ,Cell Biology ,medicine.disease ,United States ,030228 respiratory system ,Propensity score matching ,business ,computer ,SEER Program - Abstract
Purpose/Objective(s): Treatments for superior sulcus non-small cell lung cancer (SS-NSCLC) have evolved, but adequate treatments of T4 disease have not been found. The aim of our study was to evaluate the prognostic factors and optimal treatment strategy for patients with T4 SS-NSCLC. Materials/Methods: We utilized the Surveillance, Epidemiology, and End Results (SEER) database (1973–2015) to identify patients diagnosed with T4 stage SS-NSCLC (according to the 7th edition American Joint Committee on Cancer (AJCC) staging system) from 2004 to 2015; those with M1 disease were excluded. Propensity score matching (PSM) with Kaplan–Meier and Cox proportional hazards’ models was performed to estimate prognosis. Results: A total of 384 patients were included. The majority was male (59.4%) at stage IIIB (56.6%), with N2 accounting for 45.3%. A total of 47 patients underwent cancer-directed surgery, while radiotherapy alone was received by 60.2% of patients. Median overall survival (OS) and lung cancer-specific survival (LCSS) were 12 and 17 months, respectively, and the 5-year OS and LCSS rates were 15.8 and 25.4%, respectively. In the matched population, the median survival outcomes were better following surgery (OS: 25 compared with 9.0 months, P
- Published
- 2019